A 12-week study in which patients diagnosed with T2DM were treated with the DPPIV inhibitor, sitagliptin, revealed increased serum levels of PYY1-36 and improvement of glucose and non-glucose dependent insulin secretion71. The gene discussed is INS; the disease is type 2 diabetes mellitus.